Leuject

Cladribine, the active ingredient in Leuject, is an antimetabolite presented as a subcutaneous injection for use in specific hematologic malignancies and autoimmune disease. It is employed in the treatment of hairy cell leukemia and in disease‑modifying therapy for multiple sclerosis. GNH USA supplies Leuject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leuject (cladribine) is used in conditions where lymphocyte proliferation drives disease pathology. Hairy cell leukemia: induces remission by selectively targeting malignant B‑cells. Multiple sclerosis: reduces relapse frequency and disease activity by depleting pathogenic lymphocytes.

Cladribine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or erythema. - Fever or flu‑like symptoms. - Nausea or mild gastrointestinal upset. - Fatigue or weakness. - Transient lymphopenia. - Headache.

Serious or Rare Side Effects: - Severe infections, including opportunistic pathogens. - Profound or prolonged lymphopenia. - Autoimmune hepatitis or liver dysfunction. - Secondary malignancies. - Severe skin reactions such as Stevens‑Johnson syndrome. - Cardiac arrhythmias in susceptible patients.

Cladribine requires careful monitoring and patient counseling before and during therapy. - Blood count monitoring: perform complete blood counts regularly to detect lymphopenia. - Infection risk assessment: evaluate for active infections before initiating treatment. - Renal and hepatic function: assess baseline organ function and adjust if necessary. - Contraception: advise women of child‑bearing potential to use effective contraception during treatment and for a defined period after. - Live vaccines: avoid administration while immunosuppressed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine may interact with other medicines that affect immune function or blood cell production.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy agents. - Live attenuated vaccines. - Potent immunosuppressants such as high‑dose corticosteroids.

Moderate Interactions (Monitor Closely): - Drugs that alter renal excretion (e.g., nephrotoxic agents). - Antiviral agents that may increase infection risk. - Anticoagulants, requiring periodic coagulation monitoring.